IL-6 deficiency leads to reduced metallothionein-I+II expression and increased oxidative stress in the brain stem after 6-aminonicotinamide treatment

Experimental Neurology

Volumn 163, Issue 1, 2000, Pages 72-84

  Penkowa, M ^a   Hidalgo, J ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

6 aminonicotinamide (6 AN); IL 6; Inflammation; Metallothioneins; Oxidative stress

Indexed keywords

6 AMINONICOTINAMIDE; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 6; METALLOTHIONEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; BRAIN STEM INJURY; CONTROLLED STUDY; IMMUNE DEFICIENCY; KNOCKOUT MOUSE; LEUKOPOIESIS; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034111307     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2000.7383     Document Type: Article

References (63)

1. Acarin L., Carrasco J., Gonzalez B., Hidalgo J., Castellano B. Expression of growth inhibitory factor (metallothionein-III) mRNA and protein following excitotoxic immature brain injury. J. Neuropathol. Exp. Neurol. 58:1999;389-397.
2. Agullo L., Garcia A., Hidalgo J. Metallothionein-I+II induction by zinc and copper in primary cultures of rat microglia. Neurochem. Int. 33:1998;237-242.
3. Anezaki T., Ishiguro H., Hozumi I., Inuzuka T., Hiraiwa M., Kobayashi H., Yuguchi T., Wanaka A., Uda Y., Miyatake T., Yamada K., Tohyama M., Tsuji S. Expression of growth inhibitory factor (GIF) in normal and injured rat brains. Neurochem. Int. 27:1995;89-94.
4. Aschner M. The functional significance of brain metallothioneins. FASEB J. 10:1996;1129-1136.
5. Aschner M. Astrocyte metallothioneins (MTs) and their neuroprotective role. Ann. N.Y. Acad. Sci. 825:1997;334-347.
6. Aschner M., Cherian M. G., Klaassen C. D., Palmiter R. D., Erickson J. C., Bush A. I. Metallothioneins in brain - The role in physiology and pathology. Toxicol. Appl. Pharmacol. 142:1997;229-242.
7. Aschner M. Astrocytic functions and physiological reactions to injury: The potential to induce and/or exacerbate neuronal dysfunction - A forum position paper. Neurotoxicology. 19:1998;7-18.
8. Aschner M. Metallothionein (MT) isoforms in the central nervous system (CNS): Regional and cell-specific distribution and potential functions as an antioxidant. Neurotoxicology. 19:1998;653-660.
9. Brett F. M., Mizisin A. P., Powell H. C., Campbell I. L. Evolution of neuropathologic abnormalities associated with blood-brain barrier breakdown in transgenic mice expressing interleukin-6 in astrocytes. J. Neuropathol. Exp. Neurol. 54:1995;766-775.
10. Broadwell R. D., Baker-Cairns B. J., Friden P. M., Oliver C., Villegas J. C. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp. Neurol. 142:1996;47-65.
11. Broadwell R. D. Endothelial cell biology and the enigma of transcytosis through the blood-brain barrier. Adv. Exp. Med. Biol. 331:1993;137-141.
12. Budihardjo I. I., Walker D. L., Svingen P. A., Buckwalter C. A., Desnoyers S., Eckdahl S., Shah G. M., Poirier G. C., Reid J. M., Ames M. M., Kaufmann S. H. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin. Cancer Res. 4:1998;117-130.
13. Chiang C. S., Stalder A., Samimi A., Campbell I. L. Reactive gliosis as a consequence of interleukin-6 expression in the brain: studies in transgenic mice. Dev. Neurosci. 16:1994;212-221.
14. Dalton T., Pazdernik T. L., Wagner J., Samson F., Andrews G. K. Temporalspatial patterns of expression of metallothionein-I and -III and other stress related genes in rat brain after kainic acid-induced seizures. Neurochem. Int. 27:1995;59-71.
15. Eddleston M., Mucke L. Molecular profile of reactive astrocytes-implications for their role in neurologic disease. Neuroscience. 54:1993;15-36.
16. Erickson J. C., Sewell A. K., Jensen L. T., Winge D. R., Palmiter R. D. Enhanced neurotrophic activity in Alzheimer's disease cortex is not associated with down-regulation of metallothionein-III (GIF). Brain Res. 649:1994;297-304.
17. Gasull T., Rebollo D. V., Romero B., Hidalgo J. Development of a competitive double antibody radioimmunoassay for rat metallothionein. J. Immunoassay. 14:1993;209-215.
18. Dalton T., Palmiter R. D., Andrews G. K. Transcriptional induction of the mouse metallothionein-I gene in hydrogen peroxide-treated Hepa cells involves a composite major late transcription factor/antioxidant response element and metal response promoter elements. Nucleic Acids Res. 22:1994;5016-5023.
19. Haghignat N., McCandless D. Effect of 6-aminonicotinamide on metabolism of astrocytes and C6-glioma cells. Metabol. Brain Dis. 12:1996;29-45.
20. Hauser S. P., Kajkenova O., Lipschitz D. A. The pivotal role of interleukin 6 in formation and function of hematopoietically active murine long-term bone marrow cultures. Stem Cells. 15:1997;125-132.
21. Hernandez J., Hidalgo J. Endotoxin and intracerebroventricular injection of IL-1 and IL-6 induce rat brain metallothionein-I and -II. Neurochem. Int. 32:1998;369-373.
22. Hernández J., Molinero A., Campbell I. L., Hidalgo J. Transgenic expression of interleukin 6 in the central nervous system regulates brain metallothionein-I and -III expression in mice. Mol. Brain Res. 48:1997;125-131.
23. Hidalgo J., Castellano B., Campbell I. L. Regulation of brain metallothioneins. Curr. Top. Neurochem. 1:1997;1-26.
24. Hirano T., Kishimoto T. Interleukin-6: Possible implications in human diseases. Ric. Clin. Lab. 19:1989;1-10.
25. Hopkins S., Rothwell N. Cytokines and the nervous system. I. Expression and recognition. Trends Neurosci. 18:1995;83-88.
26. Hozumi I., Inuzuka T., Hiraiwa M., Uchida Y., Anezaki T., Ishiguro H., Kobayashi H., Uda Y., Miyatake T., Tsuji S. Changes of growth inhibitory factor after stab wounds in rat brain. Brain Res. 688:1995;143-148.
27. Hozumi I., Inuzuka T., Tsuji S. Brain injury and growth inhibitory factor (GIF) - A minireview. Neurochem. Res. 23:1998;319-328.
28. Hothersall J. S., Gordge M., Noronha-Dutra A. A. Inhibition of NADPH supply by 6-aminonicotinamide: Effect on glutathione, nitric oxide and superoxide in J774 cells. FEBS Lett. 434:1998;97-100.
29. Inuzuka T., Hozumi I., Tamura A., Hiraiwa M., Tsuji S. Patterns of growth inhibitory factor (GIF) and glial fibrillary acidic protein relative level changes differ following left middle cerebral artery occlusion in rats. Brain Res. 709:1996;151-131.
30. Klein M. A., Möller J. C., Jones L. L., Bluethmann H., Kreutzberg G. W., Raivich G. Impaired neuroglial activation in interleukin-6 deficient mice. Glia. 19:1997;227-233.
31. Kondo Y., Rusnak J. M., Hoyt D. G., Settineri C. E., Pitt B. R., Lazo J. S. Enhanced apoptosis in metallothionein null cells. Mol. Pharmacol. 52:1997;195-201.
32. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., Zinkernagel R., Bluethmann H., Kohler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature. 368:1994;339-342.
33. Kopf M., Ramsay A., Brombacher F., Baumann H., Freer G., Galanos C., Gutierrez-Ramos J. C., Kohler G. Pleiotropic defects of IL-6-deficient mice including early hematopoiesis, T and B cell function, and acute phase responses. Ann. N.Y. Acad. Sci. 762:1995;308-318.
34. Krinke G. J., Classen W. Spongiform neuropathy induced in dogs by prolonged, low-level administration of 6-aminonicotinamide (6-ANA). Exp. Toxicol. Pathol. 50:1998;277-282.
35. Krum J. Age-dependent susceptibility of CNS glial populations in situ to the antimetabolite 6-aminonicotinamide. Mol. Chem. Neuropathol. 26:1995;79-94.
36. Krum J. M. Experimental gliopathy in adult rat CNS: Effect on the blood-spinal cord barrier. Glia. 11:1994;354-366.
37. Lazo J. S., Kondo Y., Dellapiazza D., Michalska A. E., Choo K. H., Pitt B. R. Enhanced sensitivity to oxidative stress in cultured embryonic cells from transgenic mice deficient in metallothionein I and II genes. J. Biol. Chem. 270:1995;5506-5510.
38. Lazo J. S., Kuo S. M., Woo E. S., Pitt B. R. The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. Chem. Biol. Interact. 111-112:1998;255-262.
39. Lee D. K., Carrasco J., Hidalgo J., Andrews G. K. Identification of a signal transducer and activator of transcription (STAT) binding site in the mouse metallothionein-I promoter involved in interleukin-6-induced gene expression. Biochem. J. 337:1999;59-65.
40. Masters B. A., Quaife C. J., Erickson J. C., Kelly E. J., Froelick G. J., Zambrowicz B. P., Brinster R. L., Palmiter R. D. Metallothionein III is expressed in neurons that sequester zinc in synaptic vesicles. J. Neurosci. 14:1994;5844-5857.
41. Molinero A., Carrasco J., Hernandez J., Hidalgo J. Effect of nitric oxide synthesis inhibition on mouse liver and brain metallothionein expression. Neurochem. Int. 33:1999;559-566.
42. Munoz-Fernandez M. A., Fresno M. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog. Neurobiol. 56:1998;307-340.
43. Penkowa M., Carrasco J., Giralt M., Moos T., Hidalgo J. CNS wound healing is severely depressed in metallothionein-I and -II-deficient mice. J. Neurosci. 19:1999;2535-2545.
44. Penkowa M., Giralt M., Moos T., Thomsen P. S., Hernández J., Hidalgo J. Impaired inflammatory response to glial cell death in genetically metallothionein-I+II deficient mice. Exp. Neurol. 156:1999;149-164.
45. Penkowa M., Hidalgo J., Moos T. Increased astrocytic expression of metallothioneins I+II in brain stem of adult rats treated with 6-aminonicotinamide. Brain Res. 774:1997;256-259.
46. Penkowa M., Moos T., Carrasco J., Hadberg H., Molinero A., Bluethmann H., Hidalgo J. Strongly compromised inflammatory response to brain injury in interleukin-6 deficient mice. Glia. 25:1999;343-357.
47. Peters M., Muller A. M., Rose-John S. Interleukin-6 and soluble interleukin-6 receptor: Direct stimulation of gp130 and hematopoiesis. Blood. 92:1998;3495-3504.
48. Radi R., Beckman J. S., Bush K. M., Freeman B. A. Peroxynitrite oxidation of sulfhydryls: The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem. 266:1991;4244-4250.
49. Ridet J. L., Malhotra S. K., Privat A., Gage F. H. Reactive astrocytes: Cellular and molecular cues to biological function. TINS. 20:1997;570-577.
50. Rosenberg G. A., Kornfeld M., Estrada E., Kelley R. O., Liotta L. A., Stetler-Stevenson W. G. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res. 57:1992;203-207.
51. Sewell A. K., Jensen L. T., Erickson J. C., Palmiter R. D., Winge D. R. Bioactivity of metallothionein-3 correlates with its novel beta domain sequence rather than metal binding properties. Biochemistry. 34:1995;4740-4747.
52. Schwarz M. A., Lazo J. S., Yalowich J. C., Allen W. P., Whitmore M., Bergonia H. A., Tzeng E., Billiar T. R., Robbins P. D., Lancaster J. R. Jr. Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide. Proc. Natl. Acad. Sci. USA. 92:1995;4452-4456.
53. Spies J. M., Westland K. W., Bonner J. G., Pollard P. D. Intraneural activated T cells cause focal breakdown of the blood-nerve barrier. Brain. 118:1995;857-868.
54. Stevenson W. G. TIMp-2 reduces proteolytic opening of the blood-brain barrier by type IV collagenase. Brain Res. 576:1992;203-207.
55. Street J. C., Alfieri A. A., Koutcher J. A. Quantitation of metabolic and radiobiological effects of 6-aminonicotinamide in RIF-1 tumor cells in vitro. Cancer Res. 57:1997;3956-3962.
56. Thornalley P. J., Vasak M. Possible role for metallothionein in protection against radiation-induced oxidative stress: Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals. Biochim. Biophys. Acta. 827:1985;36-44.
57. Uchida Y., Takio K., Titani K., Ihara Y., Tomonaga M. The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron. 7:1991;337-347.
58. Yao C. P., Allen J. W., Conklin D. R., Aschner M. Transfection and overexpression of metallothionein-I in neonatal rat primary astrocyte cultures and in astrocytoma cells increases their resistance to methylmercury-induced cytotoxicity. Brain Res. 818:1999;414-420.
59. Yoshida K., Toya S. Neurotrophic activity in cytokine-activated astrocytes. Keio J. Med. 46:1997;55-60.
60. Yuguchi T., Kohmura E., Yamada K., Sakaki T., Yamashita T., Otsuki H., Kataoka K., Tsuji S., Hayakawa T. Expression of growth inhibitory factor mRNA following cortical injury. J. Neurotrauma. 12:1995;299-306.
61. Yuguchi T., Kohmura E., Yamada K., Sakaki T., Yamashita T., Otsuki H., Wanaka A., Tohyama M., Tsuji S., Hayakawa T. Changes in growth inhibitory factor mRNA expression compared with those in c-jun mRNA expression following facial nerve transection. Mol. Brain Res. 28:1995;181-185.
62. Van Lookeren Campagne M., Thibodeaux H., Van Bruggen N., Caims B., Gerlai R., Palmer J. T., Williams S. P., Lowe D. Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. Proc. Natl. Acad. Sci. USA. 96:1999;12870-12875.
63. Westland K. W., Pollard J. D., Sander S., Bonner J. G., Linington C., McLeod J. G. Activated non-neural specific T cells open the blood-brain barrier to circulating antibodies. Brain. 122:1999;1283-1291.